Low Eosinophil Phenotype Predicts Noninvasive Mechanical Ventilation Use in Patients with Hospitalized Exacerbations of COPD
Tingting Wei,Xiaocen Wang,Ke Lang,Cuicui Chen,Yansha Song,Jinlong Luo,Zhaolin Gu,Xianglin Hu,Dong Yang
DOI: https://doi.org/10.2147/JIR.S343918
IF: 4.5
2022-02-24
Journal of Inflammation Research
Abstract:Tingting Wei, &ast Xiaocen Wang, &ast Ke Lang, &ast Cuicui Chen, Yansha Song, Jinlong Luo, Zhaolin Gu, Xianglin Hu, Dong Yang Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China &astThese authors contributed equally to this work Correspondence: Dong Yang; Xianglin Hu, Email ; Rationale: Eosinophilic inflammation is related to the progression and outcomes of acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Till now, few studies have focused on low EOS in AECOPD. Objective: To reveal the clinical characteristics, therapeutic responses and prognosis of patients hospitalized of AECOPD with low EOS. Methods: The electronic database of Zhongshan Hospital, Fudan University was used. Cohort 1 included 608 patients with hospitalized AECOPD. Study population 2 consisted of 166 patients with AECOPD admission at least twice. Impact of low EOS on NIMV treatment, length of hospital stays and 12-month AECOPD-related readmission were analyzed with multivariable logistic regression model. Thirty-five hospitalized AECOPD patients were prospectively recruited as cohort 3 to explore the association between EOS and other immune cells using Spearman correlation coefficient for ranked data. Results: EOS level was suppressed on admission in AECOPD patients, and significantly improved after hospitalized treatment ( P < 0.05). For inflammatory markers, leucocytes, neutrophils and lactate dehydrogenase levels were higher, while lymphocytes, monocytes and interleukin-6 levels were lower in the low-EOS group than those in the non-low EOS group ( P < 0.05). Low EOS (EOS < 50 cells/μL) was an independent risk factor of NIMV use (OR = 1.86, 95% CI = 1.26 ∼ 2.73). The EOS percentage was positively correlated with the T cell percentage ( r = 0.46, P < 0.05) and negatively correlated with the natural killer cell percentage ( r = − 0.39, P < 0.05). The patients with low EOS had lower level of CD4 + T cell ( P < 0.05) than that of patients with non-low EOS. Conclusion: Low EOS might be a stable phenotype in patients with hospitalized AECOPD and could be used to inform NIMV management, hyperinflammatory state and impaired immunity situation. Keywords: chronic obstructive pulmonary disease, acute exacerbation, eosinophilic inflammation, prognostic phenotype, noninvasive mechanical ventilation Chronic obstructive pulmonary disease (COPD) is characterized by airflow obstruction or impaired lung function. The prevalence of spirometry-defined COPD in China was 13.7% among people aged 40 years or older. 1 Though classically mediated by neutrophilic and Th1 cells, 2 different COPD inflammatory profiles have recently gained more interest. 3 Studies demonstrated that a higher blood eosinophil (EOS) count was associated with higher risk of developing COPD in individuals from general population. 4,5 In patients with stable COPD, higher blood eosinophil count may predict increased risk of severe acute exacerbations of COPD (AECOPD). Severe AECOPD requiring hospitalization is associated with poorer outcomes, including accelerated lung function declining 6 and significant higher risk of mortality. 7 Therefore, adequately phenotyping eosinophilic inflammation in COPD is worthwhile. Previous studies mainly focused on high EOS in AECOPD by different cut-off values of 150 to 300 cells/μL. 8–10 The results supported that patients with elevated blood eosinophil counts were at higher risk of acute exacerbations. 11 COPD-related readmission rates were significantly greater at 30, 60, and 90 days and 12 months after discharge for patients with eosinophil counts >300 cells/μL (versus lesser) (OR range = 1.52–1.97). 12 It was also well established that patients with high eosinophilic exacerbations responded better to inhaled corticosteroids (ICS) therapy than patients with non-high eosinophilic exacerbations. 13 ICS combined with long-acting β2-agonists (LABA) is already recommended for AECOPD treatment if EOS ≥ 300 cells/μL. 14 However, this treatable trait presented significant variability throughout the course of COPD, making it difficult to be a reliable predictor. 15 It was demonstrated that AECOPD patients with eosinophil counts 150 cells/μL. 8 However, a study from Utah suggested that a blood eosinophil count ≤70 cells/μL identified a -Abstract Truncated-
immunology